You are on page 1of 1

Gilead to get attorney fees in hepatitis C patent fight with

Merck | Reuters
District Court for the Northern District of California, No. district judge has ruled.
(Reporting by Anya George Tharakan in Bengaluru; Editing by Leslie Adler)
In June, Gilead was freed from paying up $200 million in damages for infringing two Merck patents
related to Gilead's blockbuster drugs Sovaldi and Harvoni, after a U.S. judge found a pattern of
misconduct by Merck including lying under oath and other unethical practices.

The case is Gilead Sciences, Inc v Merck &
Co, Inc, in the U.S. 13-cv-4057.
In a filing on Thursday, U.S.
The case dates back to 2013 when Gilead
and Merck sued each other, claiming
ownership of laboratory work underlying
sofosbuvir, the active ingredient in Gilead's
Merck is trying to catch up to Gilead, which
dominates the market on a new generation of hepatitis C drugs that can cure well over 90 percent of
patients with the liver disease.
Gilead Sciences Inc is entitled to receive the attorney fees it incurred related to hepatitis C patent
litigation with drugmaker Merck & Co Inc, a U.S. District Judge Beth Labson Freeman said that
Gilead was entitled to relief from the fees it incurred while defending the case